Allogeneic, Xenogeneic, and Exogenic Hearts for Transplantation.

Area of Science:

• Transplantation immunology
• Regenerative medicine
• Xenotransplantation

Background:

• Orthotopic allogeneic heart transplantation is the only curative therapy for end-stage heart failure.
• Donor organ scarcity significantly limits the widespread application of heart transplantation.
• Alternative organ sources are crucial for addressing the global organ shortage.

Purpose of the Study:

• To explore the potential of genetically modified (GM) animal organs as an alternative source for human transplantation.
• To review the progress and challenges in xenotransplantation for cardiac replacement.
• To assess the feasibility of using gene editing and somatic cell nuclear transfer for organ development.

Main Methods:

• Utilizing gene editing and somatic cell nuclear transfer technologies to engineer humanized organs in large animal hosts.
• Preclinical xenotransplantation studies involving GM pig hearts in non-human primates (baboons).
• Investigating the efficacy of immunosuppression agents in conjunction with xenografts.

Main Results:

• Preclinical studies of GM pig hearts in baboons have established a clinical foundation.
• Two patients received cardiac xenografts from GM pigs, with survival up to two months.
• Long-term survival beyond one year remains an area requiring further investigation and improvement.

Conclusions:

• Genetically modified xenografts and exogenic organ sources hold significant promise for an unlimited organ supply.
• Overcoming challenges in xenotransplantation is key to making these strategies clinically applicable.
• Combining xenotransplantation with advanced immunosuppression could revolutionize organ replacement therapy.